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ABSTRACT: The use of fucoidan, a marine-origin bioactive
polymer, is herein proposed as a component of an innovative and
effective strategy against melanoma, one of the most aggressive
skin cancers. First, fucoidan antitumor activity, in its soluble form,
was assessed presenting increased cytotoxicity over melanoma cells
when compared to human dermal fibroblasts and keratinocytes.
After this antitumor activity validation and trying to develop a
more targeted and local strategy aiming to diminish the cytotoxic
effects over noncancer cells, fucoidan was immobilized at the
surface of an electrospun nanofiber mesh (NFM_Fu), envisioning
the development of a therapeutic patch. The maximum immobilization concentration was 1.2 mg mL−1, determined by the
Toluidine Blue Assay and confirmed by XPS. Furthermore, NFM_Fu is more hydrophilic than NFM, presenting a contact angle of
36°, lower than the 121° of the control condition. NFM_Fu was able to reduce human melanoma cell viability by 50% without
affecting human dermal fibroblasts and keratinocytes. Taken together, these results set the basis for a valuable approach for
melanoma treatment.
1. INTRODUCTION
Current treatment modalities for cancer do not achieve the
ideal therapeutic outcomes due to severe side effects
experienced by cancer patients.1 In this sense, alternative
approaches are required and, between the possibilities, there is
an increasing interest in the use of natural compounds from
marine resources as biologically active products. Brown algae
are a source of polysaccharides that may present several
biological responses.2−4 Among these marine origin materials,
fucoidan has attracted enormous interest in the last recent
years.5 Fucoidan is a polysaccharide consisting of a sequence of
sulfated fucose residues, together with other sugars, namely,
uronic acids, with a chemical structure depending on the specie
and extraction parameters, among other factors.6 Different
physicochemical properties, such as molecular weight,
carbohydrates composition, sulfation degree, and pattern
along the fucoidan backbone, have been related to its
biological activities,6−8 such as antitumor, antiangiogenic, and
anti-inflammatory.5,9 Particularly, fucoidan has been recog-
nized as a potential antitumor agent for different types of
cancers, like breast, lung, colon, and melanoma.10−14
Melanoma represents about 1% of all skin tumors. However,
it is the most aggressive and deadliest form of skin cancer,
having a very poor prognosis when it becomes metastatic.15−17
Risk factors for melanoma include sunburns during childhood,
genetic family history, and intermittent exposure to strong
sunlight.18 Current treatment modalities may be surgical
resection, chemotherapy, immunotherapy, and targeted
therapy, depending on the tumor characteristics (size, site,
and genetic profile).19,20 To improve survival rates, the
combination of different therapies is often recommended.
The lack of specificity to tumor cells is one of the major
limitations of current therapies that may result in adverse
effects and reduced efficiency.21 Trying to overcome these
limitations, the need for testing alternative strategies and
compounds, offers interesting possibilities.22
Fucoidan has been reported to inhibit melanoma develop-
ment and progression, namely, in its soluble form. Crude
commercial fucoidan extracts from Fucus vesiculosus and
Sargassum sp. showed that, despite the demonstrated cell
growth inhibition at low dosages, both extracts presented very
similar cytotoxic profiles over melanoma cells.23 In another
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attempt, similar extracts were studied, with a comparable
antiproliferative trend being crude commercial fucoidan more
cytotoxic than the extracted fucoidan at higher doses.24 It was
also demonstrated that fucoidan reduced the proliferation of
melanoma cells and melanin production in a dose-dependent
manner, producing alterations in the cells’ morphology.25 The
antitumor activity of fucoidan extracted from Undaria
pinnatifida and Fucus evanescens was evaluated over different
human cancer cell lines, namely, colon, breast, and
melanoma.13 No cytotoxic effects were observed over a
noncancer mouse epidermal cell line, whereas more
pronounced growth inhibition was observed for breast and
melanoma cells. A recent study evaluated the toxicity of
fucoidan from Fucus vesiculosus over B16 murine melanoma
cells, showing growth inhibition by regulating specific protein/
enzyme expression levels.14 However, as previously reported by
our group, not all fucoidan extracts present this interesting and
promising antitumor activity, relating its biological activity with
its chemical structure. Indeed, some fucoidan extracts may
present antitumor properties against some (not all) cell lines,
as well as having different cytotoxic concentrations.7,26 In fact,
despite the previous reports on the cytotoxic effect of different
fucoidan extracts over melanoma cells, another commercially
available fucoidan from Fucus vesiculosus was evaluated over
five different uveal melanoma cells lines not showing
antitumorigenic effects.27
Based on the discrepancy of published results, in this study,
we evaluated and validated the toxicity of soluble fucoidan not
only over human melanoma cells (WM-115 cell line), but also
over primary dermal fibroblasts and keratinocytes as models of
the main cell types characterizing the tumor microenviron-
ment. An alternative approach to face melanoma is herein
proposed, aiming to decrease the cytotoxic effects over
noncancer cells. A tailored nanofiber mesh functionalized
with fucoidan (NFM_Fu) was developed, envisioning a future
skin patch to treat melanoma in a more local, precise, and
effective way, as well as a complementary treatment after
tumor excision.
2. EXPERIMENTAL SECTION
2.1. Materials. Polycaprolactone (PCL; batch number:
MKBP7389 V; Mw = 70000−90000), chloroform, N,N-dimethylfor-
mamide (DMF), 1,6-hexanediamine (HMD), and fucoidan from
Fucus vesiculosus (Fu; batch number: SLBP3196 V; Mw = 107800)
were purchased from Sigma-Aldrich and used as received.
2.2. Production of Nanofibrous Meshes. A 15% (w/v) PCL
solution was prepared with an organic solvent mixture of chloroform
and DMF at a 7:3 ratio. The PCL solution was electrospun by
applying a voltage of 11.1 kV, a needle tip to ground collector distance
of 18 cm, and a flow rate of 1 mL h−1. After the complete processing
of 1 mL of PCL solution, the nanofibrous mesh (NFM) was allowed
to dry for 1 day.28 These processed NFMs were cut into samples of 1
× 1 cm2 for further assays.
2.3. Ultraviolet−Ozone Irradiation and Aminolysis. For the
activation of the NFM, an ultraviolet−ozone (UV−ozone) cleaner
system was used (ProCleaner 220, Bioforce Nanoscience). Both sides
of the electrospun NFMs were exposed for 90 s to UV−ozone
irradiation. After this surface activation, amine groups (−NH2) were
inserted at the surface of NFM by immersion in a 1 M HMD solution
for 1 h at 37 °C. Finally, the functionalized NFM were washed 3×
with PBS.29
2.4. Fucoidan Immobilization of NFM. Fucoidan was dissolved
in 0.1 M NaCl at different concentrations (Fu 2.5, Fu 5, Fu 7.5, and
Fu 10 mg mL −1), and 200 μL of each solution was added over
functionalized NFM in a 24-well plate. This reaction was performed
over 8 h, and after that, the solutions were removed and the
biofunctionalized NFM were left to dry overnight. In the following
day, NFM were washed twice. All steps were performed under sterile
conditions.
2.5. Quantification of Immobilized Fucoidan: Toluidine
Blue Assay. Toluidine Blue (TBO) was used to quantify the amount
of fucoidan immobilized into each NFM.30 Each sample was
immersed in 500 μL of TBO solution (0.1 M HCl, 20 mg NaCl,
and 4 mg toluidine blue O chloride) for 4 h at room temperature. The
TBO solution was removed, and the biofunctionalized NFMs were
washed until all unreacted TBO solution was removed. Afterward, the
biofunctionalized NFMs were immersed in 500 μL of a solution
containing 0.1 M NaCl and ethanol (1:4) for complete decoloration.
The amount of TBO was assessed by measuring the absorbance of the
supernatant at 530 nm using a microplate reader. The amount of
fucoidan immobilized at the surface of each NFM was calculated from
a standard curve established with fucoidan solutions at different
concentrations (Fu 2.5, Fu 5, Fu 7.5, and Fu 10 mg mL −1). In this
sense, after incubating fucoidan with TBO, the solutions were
centrifuged and the unbound TBO was removed. The pellet was then
resuspended with the above-mentioned 0.1 M NaCl and ethanol
solution and read at 530 nm.
2.6. Contact Angle. Surface hydrophilicity of NFM and NFM_Fu
was measured as the static contact angle of a standard liquid
(ultrapure water, 3 μL), at room temperature, using Contact Angle
Equipment (OCA 15plus equipment, Germany and SCA-20
software). During every determination, a motor driven syringe was
used to deposit a drop of liquid over the NFM surface. Measurements
were recorded for each sample, and the determinations were
performed in triplicate.
2.7. XPS Analysis. Analysis of the samples was performed using a
Kratos Axis-Supra instrument controlled with ESCApe software. Due
to the nonconductive nature of the samples, it was necessary to use a
coaxial electron neutralizer to minimize surface charging. The XPS
measurements were carried out using monochromatic Al−Kα
radiation (1486.6 eV). Photoelectrons were collected from a takeoff
angle of 90° relative to the sample surface. The measurement was
done in a Constant Analyzer Energy mode (CAE) with a 160 eV pass
energy and 15 mA of emission current for survey spectra and 40 eV
pass energy for high resolution spectra, also using an emission current
of 15 mA. Charge referencing was done by setting the lower binding
energy C 1s photo peak at 285.0 eV C 1s hydrocarbon peak.31 The
chemical composition of the samples was examined by XPS surface
measurements. The C 1s, O 1s, S 2p, and survey spectra were
recorded using a Kratos Axis-Supra instrument. The residual vacuum
in the X-ray analysis chamber was maintained at around 4.5 × 108
Torr. The samples were fixed to the sample holder with double-sided
carbon tape.
2.8. Biological Assays. 2.8.1. Cell Culture. Human melanoma
cells (WM-115 cell line, ATCC) were cultured in Eagle’s Minimum
Essential Medium (EMEM 30−2003, ATCC), supplemented with
10% FBS (Alfagene), 1% pen/strep (100 U/100 μg mL−1; Life
Technologies), and incubated at 37 °C in a humidified 5% CO2
atmosphere. Human dermal fibroblasts (hDFs, Gibco) were cultured
in Medium 106 (Gibco) supplemented with 10% FBS (Alfagene),
Pen/Strep (100 U/100 g mL−1; Life Technologies), and 2% Low
Serum Growth Supplement (Life Technologies). Human keratino-
cytes (hKCs) were isolated as previously published by our group.32
hKCs were cultured in Keratinocyte-SFM (Life Technologies),
supplemented with 1% Pen/Strep (100 U/100 g mL−1; Life
Technologies). The medium was changed every two days until cells
reached confluence.
2.8.2. Cell Seeding for a Soluble Fucoidan Test. Melanoma and
normal skin cells were cultured at a density of 15000 cells and were
cultured in 24-well plates. The cells were left to adhere for 4 h, and
after that, fucoidan extracts were added to adherent cells. Fucoidan
extracts were dissolved in the corresponding culture medium at
different concentrations (i.e., 0.25, 0.5, 0.75, and 1 mg mL −1). For all
the assays, a positive control was performed without fucoidan. Each
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experimental condition was tested in triplicate, and three independent
assays were performed.
2.8.3. Cell Seeding on Top of NFM. Cell seeding was performed
onto fucoidan immobilized electrospun NFMs (NFM_Fu) by
dropping a 50 μL cell suspension containing 50000 cells per
NFM_Fu. Cells were left to adhere for 4 h before culture medium
was added. NFMs subjected to surface activation and aminolysis, but
without fucoidan immobilization, were used as control (NFM_CTR).
After 1, 3, and 7 days of culture, samples were collected for cell
viability assay and SEM observation. Triplicates of each condition
were used in three independent assays (n = 3).
2.8.4. Viability Assays. The metabolic activity was determined by
the MTS assay (CellTiter 96 AQueous One Solution, Promega).
Briefly, at days 1, 3, and 7, the culture medium was removed and the
samples were rinsed with sterile PBS. A mixture of culture medium
and MTS reagent (5:1 ratio) was added to each condition as well as
to the negative control comprising no cells. Samples were left to
incubate for 3 h at 37 °C in a humidified 5% CO2 atm. Thereafter, the
absorbance of the MTS reaction medium from each sample was read
in triplicate at 490 nm (Synergy HT, BioTEK).
2.8.5. Scanning Electron Microscopy Analysis. The morphology
and distribution of cells seeded on top of the NFM_Fu or
NFM_CTR were analyzed by Scanning Electron Microscopy
(SEM). At each time point (1, 3, and 7 days), samples were collected
and fixed with 2.5% glutaraldehyde. After fixation, samples were
washed with PBS and dehydrated with increasing concentrations of
ethanol, until 100% was reached. Samples were then left to dry
overnight. In the following day, all samples were vacuum-coated with
a platinum mixture and observed at the SEM (JSM-6010 LV, JEOL,
Japan). Photographs at ×150 and ×1000 magnifications were
obtained.
2.9. Statistical Analysis. Statistical analysis was performed using
Graph Pad Prism Software. Differences between the testing
conditions were analyzed using the nonparametric test (Kruskal−
Wallis test), since the data did not follow a normal distribution and a
p < 0.05 was considered significant. Data are presented as mean ±
standard deviations.
3. RESULTS
3.1. Cytotoxicity Effects of Soluble Fucoidan over
Human Melanoma, Keratinocytes, and Dermal Fibro-
blasts. Increased toxic effects of fucoidan over human
melanoma cells started to be observed for 0.5 mg mL−1
concentration and above. At day 3, melanoma cells’ viability
reached values below 20% for those fucoidan concentrations
(Figure 1A). Regarding noncancer cells, namely, over primary
human keratinocytes, fucoidan presented significant toxicity at
day 2 for 0.25 mg mL−1 and above, presenting a toxicity
between 40 and 55% at day 3 when compared with the CTR
being dose-independent (Figure 1B). For dermal fibroblasts,
fucoidan presented significant cytotoxicity for days 2 and 3
when comparing the different concentrations, with the control
presenting a maximum toxicity around 25−30%, which was
also independent of the dosage (Figure 1C).
3.2. Quantification of Fucoidan Immobilized on NFM.
Different concentrations of fucoidan were immobilized at the
surface of NFM until its saturation concentration (10 mg
mL−1, according to the manufacture information). After
optimizing a standard curve, the different concentrations
were calculated, and it was observe that, by increasing the
Figure 1. Viability of (A) human melanoma cells (WM-115 cell line),
(B) human keratinocytes, and (C) human dermal fibroblasts exposed
to soluble fucoidan. Data were considered statistically different if p <
0.05. * indicates significant differences when compared to CTR, “+”
when compared to 0.25 mg mL−1, and “&” when compared to 0.5 mg
mL−1.
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initial concentration of fucoidan, higher amounts are
immobilized. The maximum immobilization capacity was
around 1.2 mg mL−1 for Fu10, twice the concentration of
Fu2.5 with a minimum immobilization of around 0.6 mg mL−1
(Figure 2A). The lower concentrations Fu5 and Fu2.5 are the
ones with higher immobilization percentages when compared
to the initial concentration, 16% and 26%, respectively. Fu10
and Fu7.5 have similar immobilization percentages of around
12%. Nevertheless, these are the two concentrations with more
fucoidan immobilized on the NFM (Fu7.5, 0.9 mg mL−1). In
Figure 2B it is possible to confirm the presence of fucoidan by
observing the color change of the NFMs. Fucoidan in solution
presents a light brown color, and the membranes with fucoidan
are more yellowish than the controls, which represents its
original white color. After toluidine blue staining (Figure 2C)
it is clear that the NFM that contain fucoidan becomes purple,
whereas the control is not stained.
3.3. Characterization of Bare and Fucoidan-Function-
alized NFM. 3.3.1. Contact Angle. The hydrophilicity of
NFM with or without immobilized fucoidan was determined
by the water contact angle. In the table of Figure 3 it is possible
to observe that, by increasing the concentration of immobilized
fucoidan, NFMs presented a lower contact angle, being more
hydrophilic. Electrospun NFMs without fucoidan presented a
water contact angle of 121° ± 8. On the other hand, NFMs
with immobilized fucoidan (Fu10) were much more hydro-
philic, presenting a water contact angle of 36° ± 8.
3.3.2. XPS Analysis. XPS was used to analyze the surface
chemistry of the different NFMs with or without immobilized
fucoidan. From the quantitative analysis (Table 1) it was
possible to observe that carbon and oxygen are present in all
the NFMs with immobilized fucoidan, as well as in the control
(without fucoidan), as expected since both elements are
constituents of PCL and fucoidan chemical structures. With
increasing fucoidan concentration for the functionalization of
NFMs, there was a decrease in the atomic concentration of
carbon and an increase of oxygen and, particularly, sulfur,
which originated from the sulfate groups present on
immobilized fucoidan.
A general spectrum of the control condition (Figure 4A)
indicates the presence of two main peaks representing carbon
(291.40 eV) and oxygen (537.12 eV). For Fu10 (Figure 4B),
three main peaks are detected: carbon (297.70 eV), oxygen
(544.47), and sulfur (176.0). After fucoidan immobilization, a
peak starting at 177.95 eV and ending at 167.51 eV appears,
which is attributed to the sulfur element (S 2p) from the
fucoidan chain, confirming fucoidan immobilization (Figure
4C).
3.4. Biological Response. 3.4.1. Cytotoxicity over
Human Melanoma Cells. The viability of the melanoma
cells was lower on the NFM_Fu condition than on the CTR
from day 3 onward. At days 3 and 7, NFM_Fu induced a
decrease in melanoma cell viability (Figure 5A). Specifically, at
day 3, around 70% of melanoma cells are viable, whereas at day
7 there is a viability of around 50% when compared with the
CTR. These observations were corroborated by SEM micro-
graphs (Figure 5B). Cells were able to colonize the control
NFM, covering its surface by showing an increasing number of
melanoma cells along the course of the 7 days. Oppositely, in
the case of the NFM_Fu condition, this colonization of the
mesh was not observed.
3.4.2. Cytotoxicity over Human Keratinocytes. The
immobilization of fucoidan on the NFM did not present
cytotoxic effects over seeded keratinocytes (Figure 6A). No
significant differences were observed between the CTR and the
NFM_Fu for all time points. When analyzing the SEM
micrographs, keratinocytes covered the NFM surfaces,
Figure 3. Water contact angle measurements for the NFMs without and with fucoidan immobilized at different concentrations.
Table 1. Elemental Quantitative Analysis of the Surface of












O 1s 24.03 0.38 29.65 0.44
C 1s 75.97 0.38 70.35 0.44
Fu2.5 O 1s 25.29 0.38 30.90 0.43
S 2p 0.39 0.05 0.95 0.13
C 1s 74.32 0.38 68.15 0.44
Fu5 O 1s 28.98 0.49 34.89 0.54
S 2p 0.60 0.07 1.44 0.18
C 1s 70.43 0.50 63.66 0.56
Fu7.5 O 1s 28.91 0.55 34.57 0.61
S 2p 1.07 0.09 2.56 0.22
C 1s 70.02 0.57 62.86 0.63
Fu10 O 1s 36.14 0.50 42.10 0.53
S 2p 1.41 0.09 3.28 0.21
C 1s 62.46 0.51 54.62 0.54
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presenting no morphological differences between the CTR and
the NFM_Fu conditions along the 7 days of culture.
3.4.3. Cytotoxicity over Human Dermal Fibroblasts.
NFM_Fu was also not cytotoxic for the fibroblasts (Figure
7). There were no significant differences between the CTR and
the NFM_Fu regarding the viability for all time points. When
analyzing the SEM micrographs, it is possible to observe that
dermal fibroblasts covered the surface of the NFMs, forming a
dense cell layer along time, and presenting no morphological
differences between the two conditions.
4. DISCUSSION
Melanoma is considered one of the most aggressive and deadly
skin cancers.17 If detected and treated at an early stage,
melanoma presents a high survival rate. However, when
melanoma is diagnosed in a late stage, the survival goes down
to 15−20% at 5 years.15 Although there have been some recent
advances in the field, there is still no effective therapeutic
treatment for this type of cancer. Due to an increasing
incidence of this cancer, the use of natural compounds, namely,
the ones extracted from seaweeds, has been attracting a
growing interest. It has been hypothesized that the
consumption of brown seaweeds can be somehow related
with the low incidence of melanoma in oriental countries.22,33
The best-known antitumor seaweed extract is fucoidan.
Fucoidan in the soluble form has been reported to inhibit
different types of cancer, including melanoma.22−24 However,
due its natural origin and intrinsic variability, not all fucoidan
extracts may present this antitumor behavior.7,27,34 Herein, as a
first screening, fucoidan cytotoxicity and antitumor capability
was tested in its soluble form. After this validation and trying to
diminish the potential side effects of systemic therapies, an
alternative and innovative therapeutic strategy is proposed by
incorporating fucoidan on an electrospun nanofibrous mesh,
aiming to act as a skin patch able to be easily and locally
applied at the tumor site.
First, we evaluated the toxicity of fucoidan at different
concentrations over different cell types. Besides testing with
human melanoma cells (WM-115 cell line), primary human
dermal fibroblasts and keratinocytes were also used as models
for noncancer cells, since they are the main cellular
components of skin dermis and epidermis, respectively.35 As
described by others, soluble fucoidan is highly cytotoxic for
melanoma cells. Fucoidan from different species cultured with
melanoma cell lines showed a decrease in cell viability between
40 and 60%, depending on the extracts, at 0.2 mg mL−1.13 In
another study, the effects of native and oversulfated fucoidan
were studied in tumor xenografts, where lung and melanoma
cells were injected into mice. Both fucoidan extracts were able
to reduce the tumor size after 21 days of daily injections.26
From our results, at 0.25 mg mL−1, a decrease in cells’ viability
starts to be observed. In addition, the viability of cancer cells
was below 20% for concentrations of 0.5 mg mL−1 and above.
For this same concentration of fucoidan (0.5 mg mL−1),
keratinocytes presented a viability of around 60%, whereas
dermal fibroblasts present viabilities around 70%. Even though
fucoidan presents some cytotoxic effects over noncancer cells,
fucoidan appears as a good candidate to treat melanoma.
Aiming to further decrease these cytotoxic side effects, the
immobilization of fucoidan at the surface of nanofibrous
meshes was proposed. Electrospun nanofibrous meshes are of
special interest due to an easy functionalization, a high specific
surface area and porosity, and a pore size that is smaller than
the size of most cells.36,37 The production, activation, and
insertion of amine groups at the surface of electrospun PCL
nanofibrous meshes has been previously described and
optimized by our group.28,29 Few studies have reported the
use of nanofibrous-based systems to treat melanoma, namely,
by the incorporation of chemotherapeutic drugs (i.e.,
doxorubicin and imiquimod).38,39 The use of fucoidan, a
natural compound, has never been reported to be immobilized
at the surface of electrospun nanofiber meshes. In fact, there
are only a few reports where fucoidan has been combined with
other polymers during the electrospinning process for tissue
regeneration purposes.40−42
To quantify the immobilized fucoidan, Toluidine Blue assay
was established.43,44 As it was possible to observe, control
NFMs are not stained, whereas the ones with immobilized
fucoidan are stained in blue, with increasing intensity with
fucoidan content (data not shown). The system seems not to
have reached its maximum immobilization capacity (maximum
fucoidan concentration tested was 10 mg mL −1, which is the
maximum solubility of fucoidan), but different initial
concentrations lead to different percentages of immobilization.
The immobilization of fucoidan on electrospun NFMs was
validated by contact angle and XPS analysis. As expected, the
highest fucoidan concentrations presented the highest
percentage of sulfur atoms, meaning that a higher concen-
tration of fucoidan has been immobilized. Furthermore, the
Figure 4. XPS analysis: survey spectrum of CTR (A); general spectra
of Fu10 (B); and sulfur spectra of Fu10 (C).
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immobilization of fucoidan also increased the oxygen content
due to the presence of this element in functional groups within
the polysaccharide structure, including the sulfates.45
One of the major disadvantages of some current cancer
treatments is the fact that, besides affecting the tumor, they
also have severe toxic effects over many healthy tissues.46
Therefore, when developing systems for melanoma treatment,
there is the need to evaluate their cytotoxic effects not only
over melanoma cells, but also over adjacent noncancer cells.
The fucoidan-based system was tested over primary human
keratinocytes (most common cell type in the epidermis) and
fibroblasts (most common cell type in the dermis), as well as
over a representative human melanoma cell line WM-115 (a
cell line originated from the primary tumor with competence
for metastasis) that has been used in different studies.47 This
cell line features the specific V600D (Val600Asp) mutation at
codon 600 in the BRAF gene. It also expresses PTEN loss of
function, including hemizygous deletion, although wild-type
for N-RAS, c-KIT, and CDK4 genes). It is known that tumors
are highly heterogeneous and that different responses may be
Figure 5. Cell viability (A) and representative SEM images (B) of human melanoma cells cultured on NFMs with and without (CTR) fucoidan.
Data were considered statistically different if p < 0.05.
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observed by studying different cell lines. However, as a first in
vitro validation of this system and by having in consideration
the tumor microenvironment, valuable and promising results
were achieved. In vitro results revealed a 50% decrease on
melanoma cells’ viability while maintaining the viability of
normal cells, which is an indication of the selectiveness and
effectiveness of the developed functionalized nanofibrous
membranes. When compared to the cytotoxic effects of
soluble fucoidan over the same cell types, fucoidan
immobilized at the surface of NFMs decreased the cytotoxic
effects over keratinocytes and dermal fibroblasts. These
differences may be attributed to the fact that soluble fucoidan
may be more bioactive, exerting an effective antitumor effect at
lower concentrations than when immobilized. Therefore,
fucoidan-based systems are not so cytotoxic to noncancer
cells as soluble fucoidan, although still effective over melanoma
cells.
To the best of our knowledge, despite few studies regarding
fucoidan usage as a bioactive agent, there is only one fucoidan-
based system reported in the literature that aims to treat
melanoma. Specifically, fucoidan-based nanoparticles with an
affinity to P-selectin and incorporating different chemo-
therapeutic drugs (i.e., Paclitaxel and Doxorubicin) presented
increasing toxicity when compared with untargeted drugs and
Figure 6. Cell viability (A) and representative SEM images (B) of human keratinocytes cultured on NFMs with and without (CTR) fucoidan and
control NFMs. Data were considered statistically different if p < 0.05.
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nanoparticles.48 Therefore, the proposed nanofibrous system
represents a new and innovative concept that can be further
explored for melanoma treatment, envisioning its use as an
adjuvant system in the form of a patch applied after tumor
excision.
5. CONCLUSIONS
Fucoidan, in its soluble form, presented antitumor activity
potential since it presented increased toxicity to melanoma
cells when compared with noncancer cells. Fucoidan was
immobilized at the surface of NFM trying to develop a more
local strategy to treat melanoma that can overcome some
cytotoxic side effects. This novel fucoidan-based system
presents decreased toxicity over human dermal fibroblasts
and keratinocytes, although still toxic to melanoma cells.
Therefore, it may be considered an adjuvant after tumor
excision to tackle the eventual remaining melanoma cells. The
proposed system appears as a potential effective therapeutic
alternative that should be further validated for melanoma
treatment. Furthermore, this therapy can be personalized
according to the tumor characteristics by changing its size,
shape, and treatment time.
Figure 7. Cell viability (A) and representative SEM images (B) of human dermal fibroblasts (hDFs) cultured on NFMs with or without (CTR)
fucoidan. Data were considered statistically different if p < 0.05.
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